EMEA-002072-PIP01-16-M01
Key facts
| Active substance |
(Z)-N-(3-bromo-4- fluorophenyl)-N-hydroxy-4-(2-(sulfamoylamino)ethylamino)-1,2,5-oxadiazole-3-carboximidamide
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0246/2018
|
| PIP number |
EMEA-002072-PIP01-16-M01
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms including Hodgkin lymphoma (except nervous system, haematopoietic and lymphoid tissue other than Hodgkin lymphoma)
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Incyte Corporation
Tel. +44 3301003677 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|